Genscript Biotech saw the highest growth of 1.28% in patent filings in May and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.43% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Genscript Biotech‘s patent filings and grants. Buy the databook here.
Genscript Biotech has been focused on protecting inventions in European Patent Office(EPO) with 11 publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 23% filings and 25% grants. The World Intellectual Property Organization(WIPO), United States(US), European Patent Office(EPO), and South Korea(KR) patent Office are among the top ten patent offices where Genscript Biotech is filings its patents. Among the top granted patent authorities, Genscript Biotech has 25% of its grants in European Patent Office(EPO) and 25% in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Genscript Biotech
Patents related to rare diseases and cell & gene therapy lead Genscript Biotech's portfolio
Genscript Biotech has the highest number of patents in rare diseases followed by, cell & gene therapy and genomics. For rare diseases, nearly 38% of patents were filed and no patents were granted in Q2 2024.
Multiple myeloma (kahler disease) related patents lead Genscript Biotech portfolio followed by cell therapy, and leukemia
Genscript Biotech has highest number of patents in multiple myeloma (kahler disease) followed by cell therapy, leukemia, liver cancer, and ovarian cancer.
For comprehensive analysis of Genscript Biotech's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.